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The majority of Phase I dose-finding trials in oncology
have been dominated by the traditional up-and-down
designs, such as 3+3 designs. However, in recent years,
there is an emerging interest in more innovative
model-based dose finding methods such as the Contin-
ual Reassessment Method (CRM), though examples of
implementing such adaptive designs in the medical litera-
ture remain limited. In this paper, we discuss three main
challenges faced in the implementation of CRM in a
Phase I trial in Acute Myeloid Leukaemia and a Phase I/
II trial in T-cell Lymphoma, and possible solutions.
Despite the mounting evidence of the CRM’s superior
performance in identifying the maximum tolerated dose,
it remains a challenge to communicate to clinicians the
rationale for using a method with such a greater level of
statistical complexity. Operational challenges include tri-
alists’ impression that dose-recommendations come from
a “black-box”, which contrast unfavourably with the
transparent simple rules of a 3+3 design; and concerns
that possible delays that might result. Methodological
challenges include the different variants of a CRM design
that could be considered, both from Bayesian and Maxi-
mum Likelihood frameworks, and how to choose an
appropriate design that could be adapted to specific
requirements of a trial.
We discuss proposed solutions to challenges encoun-
tered and introduce the use of Dose Transition Sample
Paths, demonstrating how this can be used to aid under-
standing in the working of such adaptive designs. We will
show that it is a valuable planning tool to achieve a
seamless, clear transition for each dose-recommendation.
Authors’ details
1MRC Midland Hub for Trials Methodology Research, University of
Birmingham, Birmingham, UK. 2Centre for Clinical Haematology, Queen
Elizabeth Hospital, Birmingham, UK. 3Oxford Cancer and Haematology
Centre, Oxford University Hospitals NHS Trust, Oxford, UK. 4Cancer Research
UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Published: 29 November 2013
doi:10.1186/1745-6215-14-S1-O75
Cite this article as: Yap et al.: Implementation of adaptive dose-finding
designs in two early phase haematological trials: clinical, operational,
and methodological challenges. Trials 2013 14(Suppl 1):O75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1MRC Midland Hub for Trials Methodology Research, University of
Birmingham, Birmingham, UK
Full list of author information is available at the end of the article
Yap et al. Trials 2013, 14(Suppl 1):O75
http://www.trialsjournal.com/content/14/S1/O75 TRIALS
© 2013 Yap et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
